Last reviewed · How we verify
NCT07039318
Mesenchymal Stem Cell Therapy in Diabetic Kidney Disease-A Double-blind, Placebo-controlled, Randomized Clinical Trial
Phase 2 trial testing Mesenchymal stem cells in Diabetic Kidney Disease in 78 participants. Completed in 31 May 2025.
28 February 2025
Quick facts
| Lead sponsor | National Institute of Blood and Marrow Transplant (NIBMT), Pakistan |
|---|---|
| Phase | Phase 2 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | triple |
| Primary purpose | treatment |
| Enrollment | 78 |
| Start date | 1 December 2022 |
| Primary completion | 28 February 2025 |
| Estimated completion | 31 May 2025 |
| Sites | 2 locations across Pakistan |
Drugs / interventions tested
- Mesenchymal stem cells — full drug profile →
- Normal Saline (Placebo) — full drug profile →
Conditions studied
- Diabetic Kidney Disease — all drugs for Diabetic Kidney Disease →
Sponsor
National Institute of Blood and Marrow Transplant (NIBMT), Pakistan
Who can join
Adults 18 to 75, any sex, with Diabetic Kidney Disease. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Diabetes had global prevalence of 9% in 2014 and is increasing alarmingly, affecting approximately 387 million people worldwide. It is strongly linked to complications, like chronic kidney failure, blindness and neurdegeneration. From 1999-2006, prevalence of chronic kidney disease (CKD) stage 1-2 was 11.5%, and stage 3-4 was 58%, while its prevalence in Pakistan is 12.5%. CKD is a pathophysiological process with multiple etiologies, eventually resulting in irreversible nephron damage and leading to End Stage Renal Disease (ESRD), rendering the patient permanently dependent on Renal Replacement. In Pakistan, the prevalence of diabetic ESRD is 22%. Only supportive management is offered, resulting in either dialysis dependency or transplant. High CKD prevalence, renal replacement therapy and associated morbidity-mortality demands more effective and easier treatment option. We propose Mesenchymal Stem Cells (MSC) therapy for reversing the chronic kidney damage caused by type2 diabetes.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT07039318
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Mesenchymal stem cells
Trials testing the same drug.
- NCT05925036 — Novel Cellular Therapy for the Treatment of Pain Associated With Chronic Pancreatitis · Phase 1 · recruiting
- NCT06727721 — Safety and Efficacy of OCN19-overexpressed Human Umbilical Cord-derived Mesenchymal Stem Cells in the Treatment of Refra · Phase 2 · recruiting
- NCT06514378 — Safety of Endobronchial Mesenchymal Stromal Cells in the Treatment of Chronic Lung Allograft Dysfunction · Phase 1 · recruiting
- NCT05872659 — Mesenchymal Stem Cells for Immune Non-responder Patients With HIV Infection · EARLY_PHASE1 · unknown
- NCT04194671 — Clinical Trial of Mesenchymal Stem Cells in the Treatment of Severe Acute Kidney Injury · Phase 1, PHASE2 · unknown
Other recruiting trials for Diabetic Kidney Disease
Currently open trials in the same condition.
- NCT07169422 — Improving Kidney Care in Type 2 Diabetes: A Study of Pharmacist Prescribing Versus Usual Care · NA · recruiting
- NCT06666283 — A Study to Evaluate the Safety, Tolerability, PK and PD of AP303 in DKD Patients · Phase 1 · recruiting
- NCT07338435 — "Residual Kidney Function and Oxidative Stress in Incremental vs Standard Peritoneal Dialysis (2 Mexican Centers)" · NA · active not recruiting
- NCT06441591 — Clinical Outcome of Vinpocetine in Diabetic Nephropathy · Phase 2, PHASE3 · recruiting
- NCT06532682 — Efficacy of Dapagliflozin in Early Diabetic Nephropathy in Type 1 Diabetes · Phase 4 · active not recruiting
Other National Institute of Blood and Marrow Transplant (NIBMT), Pakistan trials
Trials by the same sponsor.
- NCT06888973 — Mesenchymal Stem Cells Infusion in Patients With Autoimmune Diseases · Phase 1, PHASE2 · enrolling by invitation
- NCT06764329 — The Effectiveness of Allogenic Mesenchymal Stem Cells Therapy on Hair Regrowth in Androgenetic Alopecia. · Phase 1, PHASE2 · enrolling by invitation
- NCT06490627 — Unraveling the Impact of Thalidomide at Diverse Doses in Transfusion Dependent Beta Thalassemia · Phase 2 · recruiting
- NCT06288932 — Outcome Study of Conventional Steroids Vs. Steroids Combined with Mycopehnolate in Newly Diagnosed Immune Thrombocytopen · Phase 3 · completed
- NCT06490601 — Long Term Beta Thalassemia Treatment: Findings From The Extension Period · Phase 2 · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07039318 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by National Institute of Blood and Marrow Transplant (NIBMT), Pakistan
- Last refreshed: 26 June 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07039318.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing